ArticleFrontiers in pharmacology2026
Targeting CDK8 dually enhances paclitaxel antitumor efficacy and alleviates chemotherapy-induced peripheral neuropathy in breast cancer.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Paclitaxel-based chemotherapy remains a mainstay for breast cancer treatment, yet its efficacy is often limited by drug resistance and dose-limiting peripheral neuropathy. This study aimed to investigate whether CDK8 could serve as a dual target for enhancing the antitumor efficacy of paclitaxel while alleviating chemotherapy-induced neuropathic pain. Methods: We evaluated CDK8 expression in human breast cancer specimens before and after paclitaxel-containing neoadjuvant chemotherapy, as well as in paclitaxel-treated breast cancer cell lines and DRGs from syngeneic tumor-bearing mice. Loss- and gain-of-function approaches were performed to assess the functional role of CDK8 in tumor growth, paclitaxel sensitivity, and neuropathic pain behaviors. Myelin damage in the sciatic nerve was evaluated by transmission electron microscopy via G-ratio quantification. Finally, the selective CDK8/CDK19 inhibitor romaciclib was tested for its ability to enhance paclitaxel antitumor efficacy and alleviate paclitaxel induced peripheral neuropathy in a 4T1 murine breast cancer model. Results: CDK8 expression was markedly upregulated in human post-chemotherapy breast cancer tissues, paclitaxel-treated breast cancer cells, and DRGs of tumor-bearing mice. CDK8 overexpression promoted tumor growth and paclitaxel resistance, while CDK8 knockdown sensitized tumors to chemotherapy. In the peripheral nervous system, elevated CDK8 in DRGs recapitulated paclitaxel-induced mechanical allodynia, thermal hyperalgesia, and myelin damage, whereas CDK8 depletion prevented these neurotoxic effects. Pharmacological inhibition of CDK8 with romaciclib not only enhanced the antitumor efficacy of paclitaxel but also significantly alleviated paclitaxel-induced peripheral neuropathy Conclusion: CDK8 is a dual target linking chemoresistance and neurotoxicity. Inhibiting CDK8 with romaciclib may improve paclitaxel therapy while reducing its side effects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.